Underwriting Marijuana: A Balanced Approach is Required
Marijuana use in the United States has exploded over the past decades, with legal sales of various products reaching an estimated $30 billion in 2022.
Marijuana use in the United States has exploded over the past decades, with legal sales of various products reaching an estimated $30 billion in 2022.
In a new research paper, RGA experts Guizhou Hu and Taylor Pickett examine the impact of LabPiQture (LP), a commercial data product of ExamOne, on the mortality slippage of standard and better risk classes in non-fluid underwriting.
Insurers must be anticipatory, and evolve in the rapidly changing scientific, legal, and regulatory genomics landscape.
Munich Re’s medical experts respond to challenging underwriting scenarios
Fibromyalgia is a disease categorized by widespread musculoskeletal pain, fatigue and poor sleep of at least three months duration that is not characterized by any other systemic or rheumatic disorder.
In a new white paper, RGA experts Mark Ma, Guizhou Hu, and Taylor Pickett present the results of their actuarial validation of Milliman Irix® – Risk Score 3.0 with Credit, a commercial risk-scoring product that combines prescription drug, medical billing, and credit data to generate four different scores for mortality risk segmentation.
Gen Re is pleased to share this summary of key highlights from the U.S. 2023 Individual Life Accelerated Underwriting Survey.
Colorado Division of Insurance proposes first-of-its kind regulation requiring life insurers to test their underwriting process for racial and ethnic bias.
It's on a mission to make underwriting more inclusive